EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis

被引:0
作者
Peng Chen
Long Wang
Bing Liu
Hai-Zhong Zhang
Hong-Chen Liu
Zui Zou
机构
[1] Chinese People’s Liberation Army General Hospital,Department of Stomatology
[2] Second Military Medical University,Company 11
[3] the General Hospital of the Air Force of the Chinese People’s Liberation Army,Department of Stomatology
[4] Second Military Medical University,Department of Anesthesiology, Changzheng Hospital
来源
European Journal of Clinical Pharmacology | 2011年 / 67卷
关键词
EGFR; Non-small-cell lung cancer; Small-molecule tyrosine kinase inhibitors; Cetuximab;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:235 / 243
页数:8
相关论文
共 97 条
[1]  
Jemal A(2008)Cancer statistics, 2008 CA Cancer J Clin 58 71-96
[2]  
Siegel R(2008)Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clin Proc 83 584-594
[3]  
Ward E(2009)Current treatments for advanced stage non-small cell lung cancer Proc Am Thorac Soc 6 233-241
[4]  
Molina JR(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92-98
[5]  
Yang P(2002)The epidermal growth factor receptor: a new target for anticancer therapy Curr Probl Cancer 26 109-164
[6]  
Cassivi SD(2008)Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments Clin Cancer Res 14 957-960
[7]  
Stinchcombe TE(2008)Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients Jop 9 267-274
[8]  
Socinski MA(2009)Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 27 5080-5087
[9]  
Schiller JH(2005)TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 5892-5899
[10]  
Harrington D(1996)Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1-12